Current Report Filing (8-k)
December 14 2021 - 9:21AM
Edgar (US Regulatory)
0001041024
false
0001041024
2021-12-14
2021-12-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 14, 2021
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
000-23661
|
38-3317208
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
30142
S. Wixom Avenue, Wixom, Michigan
48393
(Address of principal executive offices, including
zip code)
(248) 960-9009
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each exchange on which registered
|
Common Stock, par value $0.0001
|
|
RMTI
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other
Events.
On December 14, 2021, Rockwell Medical, Inc. (the
“Company”) issued a press release regarding the Company’s receipt of a request from the U.S. Food and Drug Administration
for additional data supporting its Investigational New Drug application for its proposed Phase 2 clinical trial of Ferric Pyrophosphate
Citrate. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits The
following exhibit is being furnished herewith:
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ROCKWELL MEDICAL, INC.
|
|
|
|
Date: December 14, 2021
|
By:
|
/s/ Russell Ellison
|
|
|
Russell Ellison
|
|
|
Chief Executive Officer
|
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024